Noen ønsker rett og slett ikke å ta vaksinen
Enig med Mykle her. En del på xi som også er på musejakt vedrørende konferansen.
Det er et fritt valg. Tror du den type menneske som ikke ønsker vaksine heller ønsker å stå kontinuerlig på en medisin? 
Hvilke av forsøkene bgbio driver med gjør at de kan markedsføre medisinen sin for profylaktisk behandling ?
Man kan like gjerne se på dette forsøket som en støtte for at Bemcentinib bør gis tidlig i sykdomsforløpet, rett og slett unngå at folk havner på sykehus.
2 Likes
Hvis de ikke opplever nevneverdige bivirkninger, så ja
Har du lest lista over mulige bivirkninger for alle “hverdagslige” medisiner? Ikke alle opplever nevneverdige bivirkninger selv om de advarer mot det
Edit: skrivefeil
Husk at dette er for utslitte kropper som har vært gjennom mye og tung behandling over tid
Det blir ikke sammenlignbart med hva en normalt frisk 60-åring vil oppleve
2 Likes
5 Likes
BerGenBio ASA: Primary Insider notification
36 Likes
Bone Marrow-Derived AXL Tyrosine Kinase Promotes Mitogenic Crosstalk and Cardiac Allograft Vasculopathy
Posted: February 05, 2021
https://www.biorxiv.org/content/10.1101/2021.02.04.429773v1 (DOI)
Cardiac Allograft Vasculopathy (CAV) is a leading contributor to late transplant rejection. Although implicated, the mechanisms by which bone marrow-derived cells promote CAV remain unclear. Emerging evidence implicates the cell surface receptor tyrosine kinase AXL to be elevated in rejecting human allografts. […] Utilizing experimental chimeras deficient in the bone marrow-derived Axl gene , we report that Axl antagonizes cardiac allograft survival and promotes CAV. Flow cytometric and histologic analyses of Axl-deficient transplant recipients revealed reductions in both allograft immune cell accumulation and vascular intimal thickness. […] Inhibition of AXL-protein, in combination with current standards of care, is a candidate strategy to prolong cardiac allograft survival.
Herein we investigated the causal role of recipient and bone marrow-sourced Axl during cardiac transplantation. To accomplish this, we performed allogeneic heterotopic heart transplants in Axl bone marrow-deficient recipients and monitored key cellular and molecular indices of graft rejection. Our findings newly reveal a detrimental role of Axl sourced from the bone marrow, and in cardiac allografts, and offer new insight into how AXL-inhibition may be targeted to reduce myocardial CAV.
For selective inhibition of AXL, R428 (Apex Bio) was reconstituted in hypromellose solution (0.5% hypromellose, 0.1% Tween 80) versus solvent-only control and delivered to mice every other day via oral gavage at 25 mg/kg.
(Bemcentinib, also known as BGB324 or R428)
15 Likes
Så vi snakker om daglig Bem. som en av de faste medisiner livslang som skal hindre graftrejection hos TX pasienter (hjerte og sannsynlig andre transplantadjonsfoemer)! Det blir en stor dag for slik pasientgruppe 
(og BB investorer)
12 Likes
BERGENBIO ASA: Board approval of 2020 annual financial statement
4 Likes
BERGENBIO ASA: ANNUAL REPORT 2020
1 Like
BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
1 Like
Noen som har lest hele enda?
Fra side 17: Near Term Goals - H1 2021:
- COVID-19: Trial and Key Secondary End Point data
- AML: Proof of Concept data
- MDS: Proof of Concept data
Fra side 29: “Bemcentinib has presented a unique dual mechanism of action to combat COVID-19 infection”
Fra side 23: “Comparing oncology drugs developed with a biomarker vs those without showed an almost seven-fold improvement (10.7% vs 1.6%)”
Fra side 34: “Probability of success for a drug development programme is greatly improved in the presence of a biomarker”
Fra side 24: “BerGenBio is also developing predictive biomarkers and companion diagnostics to identify patients most likely to respond to treatment…”
Fra side 46: “In a time where many businesses have struggled, BerGenBio has been fully operational all year, without the need for government grants, and expanding as it prepares for late-stage asset development.”
16 Likes